Acrocinonide

Acrocinonide

SCHEMBL1813445

C=CC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 9/20 0.74
▸ PGR P06401 9/20 0.74
▸ HIF1A Q16665 7/20 0.74
▸ CYP3A4 P08684 7/20 0.74
▸ LMNA P02545 4/20 0.74
▸ NR1I2 O75469 1/20 0.74
▸ NPSR1 Q6W5P4 2/20 0.68
▸ HSD17B10 Q99714 4/20 0.64
▸ NFKB1 P19838 3/20 0.64
▸ CYP2C9 P11712 2/20 0.64
▸ PMP22 Q01453 2/20 0.64
▸ CYP2J2 P51589 1/20 0.64
▸ BLM P54132 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ ESR1 P03372 2/20 0.63
▸ AR P10275 3/20 0.62
▸ TSHR P16473 2/20 0.62
▸ MEN1 O00255 1/20 0.62
▸ CYP2D6 P10635 1/20 0.62
▸ KMT2A Q03164 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acrocinonide SCHEMBL11880454 1.00 NR3C1 (0.74) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL27072285 0.90 NR3C1 (0.69) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL22601611 0.90 NR3C1 (0.78) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL1638192 0.90 NR3C1 (0.78) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL12140907 0.90 NR3C1 (0.78) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL13985476 0.88 NR3C1 (0.75) NR3C1PGRHIF1ACYP3A4LMNA
Triamcinolone Acetonide SCHEMBL14661139 0.87 HIF1A (0.92) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL7741442 0.87 CYP3A4 (0.73) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL27421144 0.87 NR3C1 (0.73) NR3C1PGRHIF1ACYP3A4LMNA
SCHEMBL10337827 0.87 CYP3A4 (0.73) NR3C1PGRHIF1ACYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 — — WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 — — WO disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
CN-102119042-A Portable radiofrequency hyperthermia device with flexible treatment electrode for electric field capacitive coupled energy transfer ONCOTHERM KFT 2011-07-06 — — CN disclosed
US-7951398-B2 Pharmaceutical preparation comprising an active dispersed on a matrix NYCOMED GMBH (DE) 2011-05-31 — — US disclosed
US-20070122474-A1 Pharmaceutical preparation comprising an active dispersed on a matrix ALTANA PHARMA AG 2007-05-31 — — US disclosed
US-7175854-B2 Pharmaceutical preparation comprising an active dispersed on a matrix ALTANA PHARMA AG (DE) 2007-02-13 — — US disclosed
US-20040058896-A1 Pharmaceutical preparation comprising an active dispersed on a matrix ASTRAZENECA AB (SE) 2004-03-25 — — US disclosed
EP-1341527-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA Pharma AG (DE) 2003-09-10 — — EP disclosed
WO-2002045693-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA PHARMA AG (DE) 2002-06-13 — — WO disclosed
Send feedback